Pfizer (PFE)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$30.79+2.63%
Close 2026-11-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
Research Workspace
Put PFE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Full-year 2026 revenue in range $59.5 to $62.5 billion: Revenue guidance: $60.5B to $62.5B.
View ThesisRevenue growth is slowing — up about 1% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 15%.
View QualityManagement screens strong on earnings delivery, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskPfizer's core drugs must keep growing to justify the valuation. Revenue growth has slowed to zero percent year over year. The latest quarter beat estimates by 20.8 percent. The stock trades at 10 times earnings. That is below the 14 times peer median. The price reflects less growth than we forecast. Full-year revenue guidance sits in the $60.5 to $62.5 billion range. A cut to that guidance would break the current setup. Peer multiples imply a price roughly in line with where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. PFE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering PFE (as of Nov 2026).
Based on 4 Wall Street analysts offering 12-month price targets for PFE in the last 4 months.
Continue this research
Compare PFE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PFE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put PFE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Reaffirm full-year 2026 financial guidance
Analyst upgrade confirms positive reception of 2026 guidance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $30.79
The last 12 months of price, then the range of analyst 12-month targets from today’s $30.79.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Reaffirm full-year 2026 financial guidance
Directly reaffirms and improves 2026 financial guidance.
Advances: Reaffirm full-year 2026 financial guidance
Official guidance hike confirms strong performance and stability.
Advances: Drive operational revenue growth of launched and acquired products
Strong demand for key products supports revenue growth objective.
Advances: Reaffirm full-year 2026 financial guidance
Profit forecast increase validates financial guidance and demand.
Advances: Invest in R&D pipeline with ~20 pivotal study starts in 2026
A Phase 3 cancer-trial win supports pipeline progress, but the headline gives no trial or result details.
Advances: Invest in R&D pipeline with ~20 pivotal study starts in 2026
Phase 2 results provide pipeline evidence, but remain early-stage and do not confirm pivotal-study progress.
Growth concerns could impact full-year 2026 financial guidance.
